RADNOR, PA — Mineralys Therapeutics, Inc. (NASDAQ: MLYS) has announced an upcoming conference call and webinar to highlight the latest findings from its pivotal Advance-HTN and Launch-HTN clinical ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found that adding Mineralys' aldosterone synthase inhibitor lorundrostat to the ...

Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be ...

The Launch-HTN trial showed lorundrostat 50 mg reduced systolic blood pressure by 16.9 mmHg, with a placebo-adjusted reduction of 9.1 mmHg. The Advance-HTN trial showed lorundrostat 50 mg achieved ...

Hypertension (HTN) increases the risk of development of HF and it precedes it in 75% of cases. HF patients are nearly evenly divided between those with reduced left ventricular (LV) function or ...

This study offers hope for individuals with uncontrolled and treatment-resistant high blood pressure. Lorundrostat, a new drug that targets a hormone called aldosterone, has shown promise in ...

Oxygen re-saturation during sleep is significantly affected by sleep stage and by cardiovascular and pulmonary comorbidities.

During the event, he will discuss recent findings from the Advance-HTN and Launch-HTN clinical trials, address the challenges of uncontrolled and resistant hypertension, and explore the potential ...

SCRATCH-HTN aims to explore a new way of managing high blood pressure (BP), specifically in people who have raised BP despite being on antihypertensive medications. Participants will use an external ...